Effect of Vitamin D Supplementation in Live Birth Rate of in Vitro Fertilization Outcome

Phase 4

Recruiting

• Conditions: Infertility
• Interventions: Dietary Supplement: Vitamin D; Dietary Supplement: Placebo

• Registration Number: NCT04547530
• Lead Sponsor: The University of Hong Kong

Brief Summary

This is a randomized-controlled trial evaluating the effect of the use of vitamin D supplementation on the live birth rate in women undergoing in vitro fertilization (IVF). The hypothesis is that administration of vitamin D can increase the live birth rate for women undergoing IVF.

Detailed Description

Patients undergoing IVF treatment cycle at Queen Mary Hospital and Kwong Wah Hospital will be invited to participate in this study. Participating subjects will be randomized into either (i) vitamin D or (ii) placebo group in a 1:1 allocation ratio by computer-generated random numbers one month before IVF.

Subjects allocated to the vitamin D group will take vitamin D 50,000IU per week from recruitment for 4 weeks, followed by 50,000IU once every 2 weeks throughout the IVF cycle until fetal viability is confirmed at 6 weeks (if pregnant), after which they will be switched to Materna. If not pregnant, they will continue Vitamin D 50,000IU once every 2 weeks until 6 months from randomization, during which they can undergo frozen-thawed embryo transfer.

Subjects allocated to the placebo group will take placebo tablets which will be identical to the active drug. If pregnant and fetal viability is confirmed at 6 weeks, they will be switched to Materna. If not pregnant, they will continue the placebo tablets until 6 months from randomization, during which they can undergo frozen-thawed embryo transfer.

The clinician and patients will both be blinded to the randomization throughout the course of treatment. The live birth rate of the two groups will be compared.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2020-09-07
• Study First Submitted QC: 2020-09-07
• Study First Posted: 2020-09-14
• Study Start: 2021-02-11
• Status Verified: 2022-07
• Last Update Submitted: 2022-12-01
• Last Update Posted: 2022-12-05
• Primary Completion: 2023-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 1150

Inclusion Criteria

• Infertile women undergoing IVF
• Aged between 18 and 43 years old, inclusive, at the time of signing informed consent
• Having given voluntary written informed consent

Read More

Exclusion Criteria

• Already taking vitamin D
• Undergoing preimplantation genetic testing
• Use of donor oocytes or donor embryos
• Presence of hydrosalpinx not corrected surgically
• Active tuberculosis/ receiving therapy for tuberculosis
• History of any medical condition or medications that may predispose to vitamin D sensitivity, altered vitamin D metabolism and/or hypercalcemia, including history of renal/ureteral stones, parathyroid disease, renal or liver failure, current use of anticonvulsants, current use of steroid
• Allergy to vitamin D
• Abnormal serum calcium values

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Vitamin D	Vitamin D	Vitamin D 50,000IU per week for 4 weeks from recruitment, followed by 50,000IU per week every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery. If not pregnant, to continue vitamin D 50,000IU once every 2 weeks until 6 months from recruitment. The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice.
Placebo	Placebo	Placebo tablets identical to the active drug for 4 weeks from recruitment, followed by placebo tablets once every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery. If not pregnant, to continue placebo tablets once every 2 weeks until 6 months from recruitment. The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice.

Primary Outcome Measures

Name	Time	Method
Live birth rate	10 months	per embryo transfer procedure

Secondary Outcome Measures

Name	Time	Method
Clinical pregnancy rate	10 weeks	Presence of intrauterine gestational sac on ultrasound
Cumulative pregnancy rate within 6 months of randomization	6 months	within 6 months of randomization
Adverse events	6 months	Number of women with adverse events
Serum and follicular vitamin D levels	6 weeks	vitamin D levels
Ongoing pregnancy rate	12 weeks	Viable pregnancy beyond 8 weeks
Pregnancy rate	8 weeks	pregnancy test positive

Trial Locations

Locations (2)

Kwong Wah Hospital; 🇭🇰 Hong Kong, Hong Kong

Queen Mary Hospital, University of Hong Kong; 🇭🇰 Hong Kong, Hong Kong